povetacicept
November 30, 2026
Target timing
View details
VERTEX PHARMACEUTICALS INC / MA
FDA target dateAnnounced Nov 2, 2026
Announced timing: November 30, 2026
Original sourceWant a quick AI summary?
Dr. Izzy’s FDA Radar
| Official source | ||||
|---|---|---|---|---|
| VRTX VERTEX PHARMACEUTICALS INC / MA | povetacicept View detailsAnnounced Nov 2, 2026 Announced timing: November 30, 2026 Original sourceWant a quick AI summary? | FDA target date | November 30, 2026 Target timing | |
| INSM INSMED Inc | ARIKAYCE · Mycobacterium avium complex View detailsMycobacterium avium complex (MAC) lung disease Announced Oct 29, 2026 Announced timing: January 28, 2027 Original sourceWant a quick AI summary? | FDA target date | January 28, 2027 Target timing | |
| BMRN BIOMARIN PHARMACEUTICAL INC | VOXZOGO · achondroplasia View detailsachondroplasia Announced Nov 2, 2026 Announced timing: February 28, 2027 Original sourceWant a quick AI summary? | FDA target date | February 28, 2027 Target timing | |
| NTLA Intellia Therapeutics, Inc. | lonvo-z View detailsAnnounced Nov 5, 2026 Announced timing: March 10, 2027 Original sourceWant a quick AI summary? | FDA target date | March 10, 2027 Target timing | |
| AXSM Axsome Therapeutics, Inc. | AXS-12 · cataplexy in narcolepsy View detailscataplexy in narcolepsy Announced Nov 2, 2026 Announced timing: May 1, 2027 Original sourceWant a quick AI summary? | FDA target date | May 1, 2027 Target timing | |
| BMRN BIOMARIN PHARMACEUTICAL INC | VOXZOGO · HCH View detailsHCH Announced Nov 2, 2026 Announced timing: May 30, 2027 Original sourceWant a quick AI summary? | FDA target date | May 30, 2027 Target timing |
November 30, 2026
Target timing
VERTEX PHARMACEUTICALS INC / MA
FDA target dateAnnounced Nov 2, 2026
Announced timing: November 30, 2026
Original sourceWant a quick AI summary?
January 28, 2027
Target timing
INSMED Inc
FDA target dateMycobacterium avium complex (MAC) lung disease
Announced Oct 29, 2026
Announced timing: January 28, 2027
Original sourceWant a quick AI summary?
February 28, 2027
Target timing
BIOMARIN PHARMACEUTICAL INC
FDA target dateachondroplasia
Announced Nov 2, 2026
Announced timing: February 28, 2027
Original sourceWant a quick AI summary?
March 10, 2027
Target timing
Intellia Therapeutics, Inc.
FDA target dateAnnounced Nov 5, 2026
Announced timing: March 10, 2027
Original sourceWant a quick AI summary?
May 1, 2027
Target timing
Axsome Therapeutics, Inc.
FDA target datecataplexy in narcolepsy
Announced Nov 2, 2026
Announced timing: May 1, 2027
Original sourceWant a quick AI summary?
May 30, 2027
Target timing
BIOMARIN PHARMACEUTICAL INC
FDA target dateHCH
Announced Nov 2, 2026
Announced timing: May 30, 2027
Original sourceWant a quick AI summary?
| Official source | ||||
|---|---|---|---|---|
| REGN REGENERON PHARMACEUTICALS, INC. | Ordspono View detailsrelapsed or refractory diffuse large B-cell lymphoma (DLBCL) Announced Oct 30, 2026 Announced timing: February 2027 Original sourceWant a quick AI summary? | FDA target date | February 2027 Target timing | |
| ALNY ALNYLAM PHARMACEUTICALS, INC. | ALN-2232 · clinical data View detailsobesity and weight management Phase 1 Announced Oct 29, 2026 Announced timing: February 2027 Original sourceWant a quick AI summary? | Clinical readout | February 2027 Expected window | |
| ALNY ALNYLAM PHARMACEUTICALS, INC. | ALN-6400 · clinical data View detailsAnnounced Oct 29, 2026 Announced timing: February 2027 Original sourceWant a quick AI summary? | Clinical readout | February 2027 Expected window | |
| REGN REGENERON PHARMACEUTICALS, INC. | Libtayo View detailsAnnounced Oct 30, 2026 Announced timing: March 2027 Original sourceWant a quick AI summary? | FDA target date | March 2027 Target timing |
February 2027
Target timing
REGENERON PHARMACEUTICALS, INC.
FDA target daterelapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Announced Oct 30, 2026
Announced timing: February 2027
Original sourceWant a quick AI summary?
February 2027
Expected window
ALNYLAM PHARMACEUTICALS, INC.
Clinical readoutobesity and weight management
Phase 1
Announced Oct 29, 2026
Announced timing: February 2027
Original sourceWant a quick AI summary?
February 2027
Expected window
ALNYLAM PHARMACEUTICALS, INC.
Clinical readoutAnnounced Oct 29, 2026
Announced timing: February 2027
Original sourceWant a quick AI summary?
March 2027
Target timing
REGENERON PHARMACEUTICALS, INC.
FDA target dateAnnounced Oct 30, 2026
Announced timing: March 2027
Original sourceWant a quick AI summary?
| Official source | ||||
|---|---|---|---|---|
| AMGN AMGEN INC | ABP 206 View detailstreatment-naïve unresectable or metastatic melanoma Announced Nov 3, 2026 Announced timing: By year-end 2026 Original sourceWant a quick AI summary? | Expected FDA action | By year-end 2026 Company expectation · not a PDUFA date | |
| KYMR Kymera Therapeutics, Inc. | BROADEN2 View detailsAnnounced Oct 29, 2026 Announced timing: By year-end 2026 Original sourceWant a quick AI summary? | Clinical readout | By year-end 2026 Expected window | |
| IONS IONIS PHARMACEUTICALS INC | Sefaxersen IMAgINATION data View detailsIgAN Phase 3 Announced Nov 9, 2026 Announced timing: 2027 Original sourceWant a quick AI summary? | Clinical readout | 2027 Expected window | |
| VRTX VERTEX PHARMACEUTICALS INC / MA | inaxaplin · interim analysis data View detailsAnnounced Nov 2, 2026 Announced timing: early 2027 Original sourceWant a quick AI summary? | Clinical readout | early 2027 Expected window | |
| VRTX VERTEX PHARMACEUTICALS INC / MA | povetacicept · gMG data View detailsgMG Phase 2 Announced Nov 2, 2026 Announced timing: H1 2027 Original sourceWant a quick AI summary? | Clinical readout | H1 2027 Expected window | |
| VRTX VERTEX PHARMACEUTICALS INC / MA | suzetrigine · clinical data View detailsdiabetic peripheral neuropathy (DPN) Phase 3 Announced Nov 2, 2026 Announced timing: mid 2027 Original sourceWant a quick AI summary? | Clinical readout | mid 2027 Expected window | |
| VRTX VERTEX PHARMACEUTICALS INC / MA | VX-993 · clinical data View detailsDPN Phase 2 Announced Nov 2, 2026 Announced timing: mid 2027 Original sourceWant a quick AI summary? | Clinical readout | mid 2027 Expected window | |
| BMRN BIOMARIN PHARMACEUTICAL INC | BMN 333 · clinical data | Clinical readout | 2027 Expected window | |
| BMRN BIOMARIN PHARMACEUTICAL INC | BMN 440 View detailshypophosphatasia (HPP) Phase 1/2a Announced Nov 2, 2026 Announced timing: 2027 Original sourceWant a quick AI summary? | Clinical readout | 2027 Expected window | |
| AXSM Axsome Therapeutics, Inc. | ENGAGE View detailsBinge Eating Disorder Phase 3 Announced Nov 2, 2026 Announced timing: Q1 2027 Original sourceWant a quick AI summary? | Clinical readout | Q1 2027 Timing updated Expected window | |
| VKTX Viking Therapeutics, Inc. | VK2735 · maintenance Part 2 results | Clinical readout | 2027 Expected window | |
| RVMD Revolution Medicines, Inc. | Colorectal cancer clinical data update | Clinical readout | H1 2027 Timing updated Expected window | |
| RVMD Revolution Medicines, Inc. | RASolve 301 | Clinical readout | 2027 Expected window | |
| RVMD Revolution Medicines, Inc. | RMC-5127 | Clinical readout | 2027 Expected window | |
| ARVN ARVINAS, INC. | ARV-393 · additional monotherapy data | Clinical readout | mid 2027 Expected window | |
| ARVN ARVINAS, INC. | ARV-393 · combination data | Clinical readout | mid 2027 Expected window | |
| KYMR Kymera Therapeutics, Inc. | BREADTH View detailsmoderate to severe eosinophilic asthma Phase 2b Announced Oct 29, 2026 Announced timing: late 2027 Original sourceWant a quick AI summary? | Clinical readout | late 2027 Expected window | |
| IONS IONIS PHARMACEUTICALS INC | REVEAL View detailsAngelman syndrome Phase 3 Announced Nov 9, 2026 Announced timing: H2 2027 Original sourceWant a quick AI summary? | Clinical readout | H2 2027 Expected window | |
| AXSM Axsome Therapeutics, Inc. | FOCUS-2 View detailschildren with ADHD Phase 3 Announced Nov 2, 2026 Announced timing: H2 2027 Original sourceWant a quick AI summary? | Clinical readout | H2 2027 Expected window | |
| AXSM Axsome Therapeutics, Inc. | FOCUS-3 View detailsadolescents with ADHD Phase 3 Announced Nov 2, 2026 Announced timing: H2 2027 Original sourceWant a quick AI summary? | Clinical readout | H2 2027 Expected window | |
| AXSM Axsome Therapeutics, Inc. | SUMMIT View detailssmoking cessation Phase 3 Announced Nov 2, 2026 Announced timing: H2 2027 Original sourceWant a quick AI summary? | Clinical readout | H2 2027 Expected window | |
| AXSM Axsome Therapeutics, Inc. | SUSTAIN View detailsShift Work Disorder Phase 3 Announced Nov 2, 2026 Announced timing: H2 2027 Original sourceWant a quick AI summary? | Clinical readout | H2 2027 Timing updated Expected window | |
| ARVN ARVINAS, INC. | ARV-6723 · clinical data View detailsPhase 1 NCT07749586Announced Nov 3, 2026 Announced timing: H2 2027 Original sourceWant a quick AI summary? | Clinical readout | H2 2027 Expected window | |
| BMRN BIOMARIN PHARMACEUTICAL INC | BMN 820 · clinical data View detailsfocal segmental glomerulosclerosis (FSGS) Phase 3 Announced Nov 2, 2026 Announced timing: 2028 Original sourceWant a quick AI summary? | Clinical readout | 2028 Expected window | |
| VKTX Viking Therapeutics, Inc. | VANQUISH · extension study results | Clinical readout | 2028 Expected window |
By year-end 2026
Company expectation · not a PDUFA date
AMGEN INC
Expected FDA actiontreatment-naïve unresectable or metastatic melanoma
Announced Nov 3, 2026
Announced timing: By year-end 2026
Original sourceWant a quick AI summary?
By year-end 2026
Expected window
Kymera Therapeutics, Inc.
Clinical readoutAnnounced Oct 29, 2026
Announced timing: By year-end 2026
Original sourceWant a quick AI summary?
2027
Expected window
IONIS PHARMACEUTICALS INC
Clinical readoutIgAN
Phase 3
Announced Nov 9, 2026
Announced timing: 2027
Original sourceWant a quick AI summary?
early 2027
Expected window
VERTEX PHARMACEUTICALS INC / MA
Clinical readoutAnnounced Nov 2, 2026
Announced timing: early 2027
Original sourceWant a quick AI summary?
H1 2027
Expected window
VERTEX PHARMACEUTICALS INC / MA
Clinical readoutgMG
Phase 2
Announced Nov 2, 2026
Announced timing: H1 2027
Original sourceWant a quick AI summary?
mid 2027
Expected window
VERTEX PHARMACEUTICALS INC / MA
Clinical readoutdiabetic peripheral neuropathy (DPN)
Phase 3
Announced Nov 2, 2026
Announced timing: mid 2027
Original sourceWant a quick AI summary?
mid 2027
Expected window
VERTEX PHARMACEUTICALS INC / MA
Clinical readoutDPN
Phase 2
Announced Nov 2, 2026
Announced timing: mid 2027
Original sourceWant a quick AI summary?
2027
Expected window
BIOMARIN PHARMACEUTICAL INC
Clinical readoutAnnounced Nov 2, 2026
Announced timing: 2027
Original sourceWant a quick AI summary?
2027
Expected window
BIOMARIN PHARMACEUTICAL INC
Clinical readouthypophosphatasia (HPP)
Phase 1/2a
Announced Nov 2, 2026
Announced timing: 2027
Original sourceWant a quick AI summary?
Q1 2027
Timing updated
Expected window
Axsome Therapeutics, Inc.
Clinical readoutBinge Eating Disorder
Phase 3
Announced Nov 2, 2026
Announced timing: Q1 2027
Original sourceWant a quick AI summary?
2027
Expected window
Viking Therapeutics, Inc.
Clinical readoutAnnounced Oct 28, 2026
Announced timing: 2027
Original sourceWant a quick AI summary?
H1 2027
Timing updated
Expected window
Revolution Medicines, Inc.
Clinical readoutAnnounced Nov 4, 2026
Announced timing: H1 2027
Original sourceWant a quick AI summary?
2027
Expected window
Revolution Medicines, Inc.
Clinical readoutAnnounced Nov 4, 2026
Announced timing: 2027
Original sourceWant a quick AI summary?
2027
Expected window
Revolution Medicines, Inc.
Clinical readoutAnnounced Nov 4, 2026
Announced timing: 2027
Original sourceWant a quick AI summary?
mid 2027
Expected window
ARVINAS, INC.
Clinical readoutAnnounced Nov 3, 2026
Announced timing: mid 2027
Original sourceWant a quick AI summary?
mid 2027
Expected window
ARVINAS, INC.
Clinical readoutAnnounced Nov 3, 2026
Announced timing: mid 2027
Original sourceWant a quick AI summary?
late 2027
Expected window
Kymera Therapeutics, Inc.
Clinical readoutmoderate to severe eosinophilic asthma
Phase 2b
Announced Oct 29, 2026
Announced timing: late 2027
Original sourceWant a quick AI summary?
H2 2027
Expected window
IONIS PHARMACEUTICALS INC
Clinical readoutAngelman syndrome
Phase 3
Announced Nov 9, 2026
Announced timing: H2 2027
Original sourceWant a quick AI summary?
H2 2027
Expected window
Axsome Therapeutics, Inc.
Clinical readoutchildren with ADHD
Phase 3
Announced Nov 2, 2026
Announced timing: H2 2027
Original sourceWant a quick AI summary?
H2 2027
Expected window
Axsome Therapeutics, Inc.
Clinical readoutadolescents with ADHD
Phase 3
Announced Nov 2, 2026
Announced timing: H2 2027
Original sourceWant a quick AI summary?
H2 2027
Expected window
Axsome Therapeutics, Inc.
Clinical readoutsmoking cessation
Phase 3
Announced Nov 2, 2026
Announced timing: H2 2027
Original sourceWant a quick AI summary?
H2 2027
Timing updated
Expected window
Axsome Therapeutics, Inc.
Clinical readoutShift Work Disorder
Phase 3
Announced Nov 2, 2026
Announced timing: H2 2027
Original sourceWant a quick AI summary?
H2 2027
Expected window
ARVINAS, INC.
Clinical readoutPhase 1
NCT07749586Announced Nov 3, 2026
Announced timing: H2 2027
Original sourceWant a quick AI summary?
2028
Expected window
BIOMARIN PHARMACEUTICAL INC
Clinical readoutfocal segmental glomerulosclerosis (FSGS)
Phase 3
Announced Nov 2, 2026
Announced timing: 2028
Original sourceWant a quick AI summary?
2028
Expected window
Viking Therapeutics, Inc.
Clinical readoutAnnounced Oct 28, 2026
Announced timing: 2028
Original sourceWant a quick AI summary?
SEC 8-K filings and their exhibits from the last 90 days are scanned daily for 20 tracked companies: REGN, RVMD, IONS, AMGN, ISRG, TEM, BBNX, GH, VRTX, ALNY, INSM, SRPT, BMRN, NTLA, BEAM, KYMR, ARVN, PTCT, AXSM, VKTX. A successful scan with no qualifying events means none were verified in those sources; a failed scan retains previously verified data and is recorded separately as a source error. Later filings are checked for revisions, cancellations and announced results; unresolved timing conflicts are withheld. Blocked IR feeds and unverified company links are excluded. Not a complete catalyst inventory.